Guidance: How to handle temporary Changes in the Quality System

Recommendation
27/28 May 2025
Supervision of the Pharmaceutical Quality System: Challenges and Opportunities
The European Commission, the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have updated their questions and answers document on regulatory expectations for medicinal products for human use during the covid-19 pandemic. In the latest revision a new section on "Additional temporary GMP and GDP flexibility" was added.
In this new section, the possibility to "implement temporary changes to certain scheduled quality related tasks" is addressed. These changes in elements of the quality system are possible for the "redirection of resources to focus on supply of crucial medicines". If appropriately justified, these temporary changes "could apply to deferral of certain routine operations such as":
- Maintenance, requalification, revalidation, recalibration,
- Periodic review of PQS documents,
- On sites re-audits of suppliers, and replacement by remote audits,
- Periodic re-trainings,
- Stability testing.
However some pre-requisites need to be considered:
- Changes do not adversely impact quality, efficacy and safety of medicinal products.
- Changes should be managed transparently within the pharmaceutical quality system (PQS) and documented.
- Quality risk management should be employed.
- The Qualified Person (QP) should be made aware of any planned changes.
- Changes cannot be used to facilitate certification of batches affected by non-compliance with registered specifications.
Related GMP News
06.05.2025FDA is extending its Quality Management Maturity Programme
30.04.2025FDA Warning Letter on missing Audit Trails and Raw Data Review
23.04.2025New WHO Guideline Package: TRS 1060 published
16.04.2025EMA: QPs must provide a written final Assessment and Approval of Third-Party Audit Reports
15.04.2025Strategic Report published by the Critical Medicines Alliance
09.04.2025EMA's Plans for the next three Years